Alto Neuroscience ANRO Business Segments — Stock-Based Comp
Similar metrics at other companies
Other financials
Where this comes from
Reported directly by Alto Neuroscience in its filing.
Tagged under the XBRL concept us-gaap:AllocatedShareBasedCompensationExpense.
The official record: Alto Neuroscience’s 10-Q, filed May 13, 2026, on SEC EDGAR. View the filing →
Ask your AI about Alto Neuroscience's business segments — stock-based comp.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Alto Neuroscience's business segments — stock-based comp?
- Alto Neuroscience (ANRO) reported business segments — stock-based comp of $2.82M in Q1 2026.
- How has Alto Neuroscience's business segments — stock-based comp changed year-over-year?
- Alto Neuroscience's business segments — stock-based comp increased by 43.5% year-over-year, from $1.97M to $2.82M.
- What is the long-term trend for Alto Neuroscience's business segments — stock-based comp?
- Over 2 years (2023 to 2025), Alto Neuroscience's business segments — stock-based comp has grown at a 67.5% compound annual growth rate (CAGR), from $2.89M to $8.11M.
- What does business segments — stock-based comp mean?
- This metric captures the non-cash expense recognized for equity-based awards granted to employees and directors within the reportable segment. It reflects the cost of aligning management and staff incentives with long-term shareholder value through stock options or restricted stock units. Analyzing this expense is critical for understanding the dilutive impact on shareholders and the total cost of talent acquisition.